JD.Com Inc vs Tilray Brands Inc — how do they compare? JD.Com Inc trades at $27.09 (market cap $36.62B), while Tilray Brands Inc trades at $3.54 (market cap $530.54M). The key difference: JD.Com Inc is far larger — about 69× Tilray Brands Inc's market cap, and JD.Com Inc pays a 3.72% dividend while Tilray Brands Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold JD.Com Inc for 85 Days and Tilray Brands Inc for 31 Days on average.
| JD | TLRY | |
|---|---|---|
Market Cap | $36.62B | $530.54M |
Volume | 6,571,477 | 9,099,075 |
Sector | Consumer Cyclical | Health |
52-Week High | $34.53 | $17.20 |
52-Week Low | $25.19 | $3.54 |
Typical Hold Time | 85 Days | 31 Days |
Enterprise Value | $19.26B | $684.46M |
Dividend Yield | 3.72% | — |
Signals from Pluang's Aura AI — not financial advice
JD.com (JD) trades at $26.91, down 0.44% on the day, amid mixed technical signals but strong fundamental value. The stock shows a bullish overall technical signal despite bearish moving averages, with key support at $26. Valuation metrics are attractive with a P/E of 17.9 and P/S of 0.2, while recent earnings beats and a pending Q3 report highlight operational strength. Positive news includes potential EU approval for the $2.5 billion Ceconomy acquisition (Reuters, 2026-10-02).
The outlook remains favorable given deep undervaluation, robust cash flow, and analyst consensus pointing to 33% upside to the $35.86 price target. Risks include revenue growth deceleration, regulatory scrutiny from EU probes, and macroeconomic pressures on Chinese equities. The stock's net cash position and institutional accumulation support a constructive view for long-term investors.
Tilray Brands (TLRY) trades at $3.59, down 3.36% on the day and near 52-week lows, with bearish technical indicators dominating. The company reported $821 million in revenue for 2025 but posted a massive $2.19 billion net loss due to impairment charges. Recent earnings have consistently missed expectations, though analyst consensus remains cautiously optimistic with a $65.01 price target. The stock faces significant headwinds from ongoing profitability challenges and cannabis industry volatility.
TLRY presents a high-risk opportunity with potential upside if management can achieve profitability and capitalize on cannabis reform catalysts. However, persistent losses, negative cash flow, and competitive pressures create substantial downside risk. Investors should weigh the speculative nature against potential regulatory catalysts in the coming months.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
JD.com is China's second-largest e-commerce company after Alibaba in terms of gross merchandise volume, offering a wide selection of authentic products at competitive prices, with speedy and reliable delivery. The company has built its own nationwide fulfilment infrastructure and last-mile delivery network, staffed by its own employees, which supports both its online direct sales, its online marketplace and omnichannel businesses.
Read more on JD →Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →